| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/05/2011 | CN101935640A Bacterial colony induction signal degrading enzyme and coding gene and application thereof |
| 01/05/2011 | CN101934081A Magnetic nano lamellar hydroxyapatite and DNA composite as well as preparation method and application thereof |
| 01/05/2011 | CN101508999B Recombinant toxoplasma protein and uses thereof |
| 01/05/2011 | CN101095957B Medicinal composition including fibroblast growth factor acceptor 2 III c analogue gene |
| 01/04/2011 | US7863470 protein expression levels higher than linear polyethylenimine alone, and twice that of branched polyethylenimine, but without any significant loss in cell viability; sterols such as cholesterol conjugated via the haloformate ester reaction; drug delivery of the nucleic acids into cells |
| 01/04/2011 | US7863436 Short interfering RNA for use in treatment of cell proliferative disorders |
| 01/04/2011 | US7863252 Chimeric oligonucleotide for use in diagnosis and treatment of tissue destruction, necrosis and inflammatory diseases |
| 01/04/2011 | US7863251 Hepatic stellate cell specific promoter and uses thereof |
| 01/04/2011 | US7863250 Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
| 01/04/2011 | US7863244 Peptides |
| 01/04/2011 | US7862818 Using chemokine specific immunoglobulin to prevent and treat inflammatory bowel disease, colitis and/or sarcoidosis |
| 01/04/2011 | US7862816 Identifying ephrin inhibitors for use in treatment and prevention of cell proliferative and angiogenesis disorders; antitumor agents |
| 01/04/2011 | US7862814 Method of inhibiting the proliferation of B cell cancers using TACI-immunoglobulin fusion proteins |
| 01/04/2011 | CA2449054C Integrin targeting liposome for nucleic acid delivery |
| 01/04/2011 | CA2401545C Mutated cyclin g1 protein |
| 01/04/2011 | CA2389206C Activation of hcv-specific t cells |
| 01/04/2011 | CA2388301C Modified gp100 and uses thereof |
| 01/04/2011 | CA2382848C Diagnostics and therapeutics for osteoporosis |
| 01/04/2011 | CA2350127C Avipox vector coding an hiv antigen and a cytokine |
| 01/04/2011 | CA2335645C Use of interferon alpha 5 in the treatment of viral liver diseases |
| 01/04/2011 | CA2304988C Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders |
| 01/04/2011 | CA2268865C Anti-p53 single-chain antibody fragments and their uses |
| 01/04/2011 | CA2248869C Allele suppression |
| 01/04/2011 | CA2163439C Methods of using bcl-2 for the therapeutic treatment and prevention of diseases |
| 01/04/2011 | CA2142575C Melanoma associated antigenic polypeptide, epitopes thereof and vaccines against melanoma |
| 12/30/2010 | US20100331536 CA125 gene and its use for diagnostic and therapeutic interventions |
| 12/30/2010 | US20100331535 Conjugates and compositions for cellular delivery |
| 12/30/2010 | US20100331528 Isolated Antibodies Against Biologically Active Leptin-Related Peptides |
| 12/30/2010 | US20100331395 Decoy-containing pharmaceutical compositions and method of using the same |
| 12/30/2010 | US20100331390 Effects of apolipoprotein b inhibition on gene expression profiles in animals |
| 12/30/2010 | US20100331214 siRNA Targeting Survivin |
| 12/30/2010 | US20100330554 Diagnostic kit for solid cancer and medicament for solid cancer therapy |
| 12/30/2010 | US20100330121 Recombinant alphavirus-based vectors with reduced inhibition of cellular macro-molecular synthesis |
| 12/30/2010 | US20100330101 BIFUNCTIONAL CpG OR OLIGO-/POLYNUCLEOTIDE AND TOXIN OR ENTEROTOXIN CONTAINING COMPOSITION |
| 12/30/2010 | US20100330062 Klotho protein and related compounds for the treatment and diagnosis of cancer |
| 12/30/2010 | US20100330053 Mixed-cell gene therapy |
| 12/30/2010 | US20100330051 Polypeptide having an improved cytosine deaminase activity |
| 12/30/2010 | US20100330042 Use of Proinsulin for the Preparation of a Neuroprotective Pharmaceutical Composition, Therapeutic Composition Containing it and Applications Thereof |
| 12/30/2010 | US20100330037 Adenoviral systems and the uses thereof |
| 12/30/2010 | US20100329988 Method for Identifying Within a Mammal a DNA Encoding A Physiologically Active Polypeptide |
| 12/30/2010 | US20100329982 Particles with inducible change of shape |
| 12/29/2010 | WO2010151773A2 Methods and compositions for increasing the activity of inhibitory rna |
| 12/29/2010 | WO2010151674A2 Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
| 12/29/2010 | WO2010151671A2 Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
| 12/29/2010 | WO2010151664A2 Compositions and methods for treating cancer and modulating stress granule formation |
| 12/29/2010 | WO2010151640A2 Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease |
| 12/29/2010 | WO2010151638A1 Jnk inhibitors for use in treating spinal muscular atrophy |
| 12/29/2010 | WO2010151420A1 Compositions and methods for treatment of insulin-dependent diabetes mellitus |
| 12/29/2010 | WO2010150819A1 Therapeutic agent for ischemic cerebrovascular disorders |
| 12/29/2010 | WO2010150650A1 Novel method for maintaining stem cells in an undifferentiated state |
| 12/29/2010 | WO2010150525A1 Urate transporter, as well as method and kit for evaluating urate transport-related disease factor and inflammation-related disease factor, and test sample and drug |
| 12/29/2010 | WO2010149785A1 Cationic liposomes for the delivery of high molecular weight compounds |
| 12/29/2010 | WO2010125471A3 Gene vector |
| 12/29/2010 | EP2267458A2 Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
| 12/29/2010 | EP2267454A2 Diagnosis and prevention of cancer cell invasion |
| 12/29/2010 | EP2267158A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
| 12/29/2010 | EP2267157A2 Identification of surface-associated antigenes used for the diagnosis and therapy of tumours |
| 12/29/2010 | EP2267156A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
| 12/29/2010 | EP2267140A1 Improved genetic elements providing high levels of expression |
| 12/29/2010 | EP2267118A1 Method for production of transfected cell |
| 12/29/2010 | EP2267031A1 Endothelial cell specific antibodies and uses thereof |
| 12/29/2010 | EP2267026A1 Albumin fusion proteins |
| 12/29/2010 | EP2267013A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy |
| 12/29/2010 | EP2267012A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy |
| 12/29/2010 | EP2267011A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy |
| 12/29/2010 | EP2266997A1 Modulation of C-reactive protein expression |
| 12/29/2010 | EP2266995A1 Oligonucleotides against HIV infection and its application in the prevention and treatment of acquired immune deficiency syndrome |
| 12/29/2010 | EP2266656A2 Devices for delivering a biologically active agent to the ocular sphere of a subject |
| 12/29/2010 | EP2266628A2 Method of determining the susceptibility to bone meatastases by EPhA2 expression |
| 12/29/2010 | EP2266627A1 Single-stranded oligodeoxynucleotide mutational vectors |
| 12/29/2010 | EP2266626A1 Composition for external application comprising transcription factor decoy as active ingredient |
| 12/29/2010 | EP2266616A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy |
| 12/29/2010 | EP2266615A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy |
| 12/29/2010 | EP2266613A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy |
| 12/29/2010 | EP2266612A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy |
| 12/29/2010 | EP2266594A1 VEGF for use in the treatment of central nervous system disorders |
| 12/29/2010 | EP2266550A1 Antagonists of ß-catenin for preventing and/or treating neurodegenerative disorders |
| 12/29/2010 | EP2266543A2 Non-polymeric hematopoietic cell clots for delivery of active agents |
| 12/29/2010 | EP2265717A2 Use of sirna to achieve down regulation of an endogenous gene in combination with the use of a sense construct to achieve expression of a desired polynucleotide |
| 12/29/2010 | EP2265291A2 Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration |
| 12/29/2010 | EP1599503B1 Endothelial cell specific antibodies and uses thereof |
| 12/29/2010 | EP1529062B1 Therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signal transduction |
| 12/29/2010 | EP1504095B2 Site specific listeria integration vectors and methods for using the same |
| 12/29/2010 | EP1494705B1 A composition and method for killing of tumours |
| 12/29/2010 | EP1425305B1 Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses |
| 12/29/2010 | EP1315519B1 Pharmaceutical compositions and methods useful for treating cancer or liver fibrosis |
| 12/29/2010 | CN101932339A Dendritic cell vaccine compositions and uses of same |
| 12/29/2010 | CN101928747A Application of E3 ubiquitin ligase CHIP in gliomatosis cerebri disease |
| 12/29/2010 | CN101928696A Preparation and application of prostate cancer targeting adenovirus |
| 12/29/2010 | CN101928347A Anti-carcinoembryonic-antigen (CEA) antibody and application thereof |
| 12/29/2010 | CN101928345A Human source antibody and humanization remolding method thereof |
| 12/29/2010 | CN101928344A Human monoclonal antibodies against cd20 |
| 12/29/2010 | CN101926989A Recombinant attenuated Salmonella typhimurium vector vaccine for expressing JEV (Japanese Encephalitis Virus) immunogenic gene as well as preparation method thereof |
| 12/29/2010 | CN101926981A Methods of treating neurological conditions with hematopoietic growth factors |
| 12/29/2010 | CN101926824A Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells |
| 12/29/2010 | CN101560514B Bridge molecule 1-siRNA interference sequence and fusion expression vector thereof |
| 12/29/2010 | CN101538745B Method for preparing biodegradable polymerultrafine fiber capable of controllably releasing genomic medicine |
| 12/29/2010 | CN101200482B shRNA accelerating carcinoma cell apoptosis and uses thereof |
| 12/29/2010 | CA2784286A1 Urate transporter, method and kit for evaluating urate transport-related disease factor and inflammation-related disease factor, and test sample and drug |
| 12/29/2010 | CA2765889A1 Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |